Growth hormone treatment in young children with Down's syndrome: effects on growth and psychomotor development

G Annerén1, T Tuvemo, C Carlsson-Skwirut

  • 1Department of Genetics and Pathology, Unit of Clinical Genetics, Uppsala University Children's Hospital, S-751 85 Uppsala, Sweden. goran.anneren@ped.uas.lul.se

Insights

Growth hormone (GH) treatment improved linear growth in children with Down syndrome, but did not impact cognitive or motor development. Growth velocity decreased after treatment cessation.

Area of Science:

  • Pediatrics
  • Endocrinology
  • Genetics

Background:

  • Down syndrome is characterized by learning disabilities and short stature.
  • Insulin-like Growth Factor I (IGF-I), regulated by Growth Hormone (GH), may play a role in brain development.

Purpose of the Study:

  • To investigate the long-term effects of GH on linear growth and psychomotor development in young children with Down syndrome.
  • To assess the impact of GH on skeletal maturation, IGF-I, IGF binding proteins (BP), and cerebrospinal fluid (CSF) IGF-II.

Main Methods:

  • A three-year study involving 15 children with Down syndrome (ages 6-9 months).
  • Treatment with GH was administered, with regular monitoring of growth parameters, psychomotor development, and biochemical markers.
  • A control group of children with Down syndrome was used for comparison.

Main Results:

  • GH treatment increased mean height SDS from -1.8 to -0.8, while the control group's height fell from -1.7 to -2.2 SDS.
  • Growth velocity decreased after GH treatment cessation.
  • No significant improvements were observed in head circumference, mental development, or gross motor skills.
  • Serum IGF-I and IGFBP-3 levels normalized during GH treatment.

Conclusions:

  • GH treatment effectively improves linear growth velocity in children with Down syndrome.
  • GH therapy does not influence head circumference, cognitive function, or gross motor development in this population.
  • The positive effects on growth velocity are not sustained after treatment discontinuation.
Abstract

Related Concept Videos

Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Major Hormones and Their Functions01:27

Major Hormones and Their Functions

Hormones, the biochemical messengers produced by endocrine glands, are pivotal in regulating bodily functions and maintaining homeostasis. Each hormone's balance is crucial; imbalances can lead to significant physiological disruptions. Major hormones include oxytocin, cortisol, epinephrine, estrogen, testosterone, thyroxine, growth hormone, insulin, and glucagon.
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and lactation.
Physical Growth During Infancy and Toddlerhood01:18

Physical Growth During Infancy and Toddlerhood

Physical growth is especially rapid during the first three years of life, with the greatest rate in the first few months after birth. Although children continue to gain height and weight throughout infancy and toddlerhood, the rate of growth gradually slows during the second and third years. At most ages, boys are typically slightly taller and heavier than girls, reflecting a common pattern of early physical development.Changes in Body ProportionsAs infants become toddlers, their body...